Personalized functional profiling using patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid.

Date publication

décembre 2022

Journal

Cancer biology & therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PESSAUX Patrick

Tous les auteurs :
Kim H, El-Khoury V, Schulte N, Zhan T, Betge J, Cousin L, Felli E, Pessaux P, Ogier A, Opitz O, Ku B, Ebert MP, Kwon YJ

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35193475

Résumé

Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Personalized functional profiling (PFP), i.e. drug screening, was performed in spheroids obtained from the patient's liver metastasis to identify potential therapeutic options. The drug screening results revealed cediranib, an antiangiogenic drug, as a hit drug for this patient, from a library of 66 Food and Drug Administration (FDA)-approved and investigational drugs. Based on the PFP results and the reported evidence of clinical efficacy of bevacizumab and capecitabine combination in gastro-intestinal neuroendocrine tumors, this combination was given to the patient. Four months later, the pleural effusion and pleura carcinosis regressed and the liver metastasis did not progress. The patient experienced 2 years of a stable disease under the PFP-guided personalized treatment.

Mots clés

Personalized functional profiling, antiangiogenic therapy, drug screening, lung carcinoid, neuroendocrine tumors, personalized medicine, pharmacotyping, precision medicine, spheroids

Référence

Cancer Biol Ther. 2022 Dec 31;23(1):96-102